Skip to main content

The hormones, plainly

The vocabulary, before the prescribing conversation

One focused page per hormone, in plain language. Pick the one you came here for.

In 30 seconds

  • Estrogen and progesterone do most of the day-to-day work. Testosterone matters too.
  • FSH and LH are lab numbers, not symptoms. They rarely change the plan.
  • This page is vocabulary, not a prescription. Pick a hormone below, then head to treatments.
OptionalHow they work together, in one map

How they fit together

One conversation, four hormones, talking to each other

The brain (hypothalamus and pituitary) sends FSH and LH down to the ovaries. The ovaries answer back with estrogen and progesterone, on a monthly rhythm. Testosterone runs alongside, made in the ovaries and adrenals, on its own quieter dial. In perimenopause that loop starts to misfire. This is why one symptom is rarely traceable to one hormone.

OptionalIs this you? Framed for your stage

If you came here from a search

Progesterone is not the same thing as the progestin in your pill

Search results for "progesterone" mostly show contraception, where the active ingredient is a progestin. Perimenopause and MHT use micronized progesterone, body-identical, lower dose, usually at night. Same family, different drug.

Read the progesterone page

The synthetic family, and the newer drugs

Progestins, Premarin, ethinyl estradiol, tibolone, NK3 antagonists, BHRT

Most old HRT fear traces back to one specific old combination. Most "bioidentical" marketing sells what the regulated version already does. And NK3 antagonists like fezolinetant are a genuinely new option for people who can't take estrogen.

Read the synthetics page

If you've had a hormone-sensitive cancer

The conversation is different, but it isn't closed

The answer used to be a flat no. It's more careful than that now, and it's decided with your oncology team and a menopause-aware doctor, not a search engine.

The detailFour things worth knowing
  • Local vaginal estrogen is a separate question from systemic MHT. The doses are tiny, the systemic absorption is low, and current guidance from major menopause societies treats it as discussable for many people after breast cancer — including those on aromatase inhibitors — when GSM is hurting daily life.
  • Non-hormonal options for hot flashes have moved on. SSRIs and SNRIs (with caveats around tamoxifen interactions), gabapentin, oxybutynin, and the newer NK3 receptor antagonists (fezolinetant, with elinzanetant on the way) give people who can't take systemic estrogen real levers for vasomotor symptoms.
  • Treatment-induced menopause is its own pathway. Chemotherapy, ovarian suppression, oophorectomy, and aromatase inhibitors land harder and faster than the gradual perimenopause story most resources are built around.
  • "No MHT" is a starting position, not the whole answer. Even when systemic MHT is off the table, sleep, mood, joint pain, GSM, libido, bone, and brain symptoms still need a plan.

What this page isn't

A primer, not a prescription

Vocabulary, so the appointment makes sense. Doses and choices live on treatments.